virus PCR. Th e culture grew Pseudomonas stutzeri . AZA was held and the patient was treated with cefepime for 2 weeks. Th e patient recovered from the meningitis but continued to have diarrhea with moderate-to-severe endoscopic disease activity. Given the severity of her disease, primary non-response to certolizumab and the fact that her infection was adequately controlled with antibiotics, Vedolizumab treatment was eventually resumed along with a tapering course of prednisone. Th e patient, however, ultimately required fecal diversion for persistent disease activity.
Patients with CD are at an increased risk for serious infections, due to both diseaserelated infections and immunosuppressive therapies ( 2 ) . By selectively inhibiting α 4β 7 integrin interaction with mucosal addressin cell-adhesion molecule (MAdCAM1), vedolizumab blocks T-lymphocyte traffi cking to the gut and nasopharynx where MAdCAM1 is expressed on the vascular endothelium. Th e phase 3 randomized controlled trial for CD revealed a slightly higher numeric but not statistically significant risk for serious infections with VDZ as compared with placebo (relative risk 1.48, 95% confi dence interval: 0.67, 3.24) ( 1 ) . During the phase 3 trials for ulcerative colitis and CD, 2 cases of viral meningitis and 1 case of Listeria meningitis were reported in vedolizumab-treated patients ( 3 ) . Th e case of Listeria meningitis occurred in the setting of concomitant AZA therapy and systemic steroids. Although an estimated 10% of the population is colonized with Listeria monocytogenes , listeriosis is typically only seen in immunosuppressed individuals ( 4 ) . Th e occurrence of Listeria meningitis may potentially have been secondary to gut translocation in an immunosuppressed individual.
Pseudomonas stutzeri , an aerobic Gramnegative bacillus, is typically an asymptomatic colonizer of the respiratory tract and rarely pathogenic. Although bacteremia and pneumonia have been reported, meningitis is extremely rare with <5 cases reported to date, all in the setting of systemic immune suppression ( 5-8 ). Our patient was receiving AZA and budesonide and had only recently discontinued certolizumab. Th e timing of infection with initiation of vedolizumab, however, raises the possibility of a To the Editor: Vedolizumab, an α 4β 7 integrin antagonist, has recently been approved for induction and maintenance of Crohn's disease (CD) ( 1 ) . Th e gut-selective immune suppression of vedolizumab provides a more favorable safety profi le as compared with conventional tumor necrosis factor antagonists; however, gut or systemic infections entering through the gut remain a potential concern. We present a patient who developed meningitis from an opportunistic pathogen potentially entering from the nasopharynx aft er initiating vedolizumab.
Pseudomonas

Meningitis
A 19-year-old woman had CD with ulceration of the terminal ileum and colon at colonoscopy and associated symptoms of abdominal pain and diarrhea, despite therapy with certolizumab pegol, azathioprine (AZA) 2.1 mg/kg and budesonide 9 mg daily. Certolizumab was discontinued and vedolizumab 300 mg intravenously was administered ~6 weeks later, alongside AZA and budesonide. Th e patient presented to the emergency department 10 days aft er her fi rst vedolizumab infusion with fever, body aches, photophobia, and headache. Th e patient had a fever (39.5°C), tachycardia, nuchal rigidity, and right lower quadrant abdominal tenderness. White blood cell (WBC) count was 8.9×10
9 cells/ml with 16% bands. Empiric treatment for meningitis was initiated with cefepime, ampicillin, vancomycin, and acyclovir, as well as methylprednisone. Lumbar puncture (on antibiotics) revealed an opening pressure of 21 cm water, WBC of 3 cells, glucose of 49 mg/dl, total protein of 10 mg/dl, and negative herpes simplex with important implications for national and international health policy strategies to decrease the burden of disease and death from HCC in Africa.
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Th e authors declare no confl ict of interest. drug-related adverse event. Although vedolizumab has a gut-selective mechanism, there is a slight increase in risk of infections which is largely attributed to an increased incidence of upper respiratory tract infections (23 vs. 19%) and inhibition of α 4β 7/ MAdCAM1 interaction in the naso pharynx ( 1 ) . Th erefore, inhibition of leukocyte traffi cking and immune surveillance by vedolizumab in the nasopharynx may have led to bacterial translocation in a patient colonized with this bacteria, resulting in meningitis. Although a clear causal association cannot be made given the patient's concomitant AZA use and recent discontinuation of certolizumab, this potential association warrants additional future scrutiny in patient populations where respiratory and nasopharyngeal colonization with resistant organisms is common. 
